2,6,9-trisubstituted purines: optimization towards highly potent and selective CDK1 inhibitors

  • Bioorg Med Chem Lett. 1999 Jan 4;9(1):91-6. doi: 10.1016/s0960-894x(98)00691-x.
P Imbach  1 ,  H G Capraro ,  P Furet ,  H Mett ,  T Meyer ,  J Zimmermann
Affiliations
  • 1. Novartis Pharmaceuticals, Novartis Limited, Basel, Switzerland.
PMID: 9990463 DOI: 10.1016/s0960-894x(98)00691-x
Abstract

Novel 2,6,9-substituted purine derivatives represent a class of potent and selective inhibitors of CDK1/cyclinB. The synthesis, SAR and biological profile of selected compounds are described.

Products